What is HC Wainwright’s Forecast for MIRM FY2025 Earnings?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research note issued on Tuesday, January 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.19) per share for the year, up from their prior forecast of ($0.35). HC Wainwright has a “Buy” rating and a $102.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2025 earnings at $0.08 EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($0.05) EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The business had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. During the same quarter in the prior year, the business posted ($0.30) EPS. The business’s revenue for the quarter was up 47.1% on a year-over-year basis.

Other analysts also recently issued research reports about the stock. Citizens Jmp boosted their price objective on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Finally, Morgan Stanley boosted their target price on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $102.00.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $90.65 on Thursday. The business has a 50 day moving average price of $74.10 and a 200 day moving average price of $68.68. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The stock has a market cap of $4.66 billion, a price-to-earnings ratio of -105.41 and a beta of 0.48. Mirum Pharmaceuticals has a fifty-two week low of $36.88 and a fifty-two week high of $91.80.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Comerica Bank increased its position in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period. AQR Capital Management LLC grew its stake in shares of Mirum Pharmaceuticals by 307.3% in the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after purchasing an additional 37,028 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 7.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after purchasing an additional 1,720 shares during the period. Caxton Associates LLP purchased a new stake in shares of Mirum Pharmaceuticals during the first quarter worth approximately $217,000. Finally, Empowered Funds LLC lifted its holdings in shares of Mirum Pharmaceuticals by 15.4% during the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after purchasing an additional 5,120 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.